Search

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

Meet Stefan Fröhling, our November volunteer of the month

Can you tell us what you do for EHA and when you started?
I first learned about EHA in 2002 when I attended the 7th Congress of EHA in Florence.

Read more

Meet Stefan Fröhling, our November volunteer of the month

Can you tell us what you do for EHA and when you started?
I first learned about EHA in 2002 when I attended the 7th Congress of EHA in Florence.

Read more

Choose your membership

Wherever you are in the world, you can join our vibrant community and benefit from our rigorous resources and career-enhancing opportunities.

Read more

Policy on double awarding

We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.

Read more

Policy on double awarding

We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.

Read more

Policy on double awarding

We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.

Read more